Reuters logo
BRIEF-Fortress Biotech announces final patient dosed in phase 1B trial of cael-101
May 4, 2017 / 12:34 PM / 7 months ago

BRIEF-Fortress Biotech announces final patient dosed in phase 1B trial of cael-101

May 4 (Reuters) - Fortress Biotech Inc:

* Fortress Biotech announces final patient dosed in phase 1b trial of cael-101 for the treatment of al amyloidosis

* Expects to readout preliminary phase 1B data mid-2017, and full data by end of year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below